Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01307800 · ClinicalTrials.gov registry record · Phase 3
A Study of LY2140023 in Patients With Schizophrenia
A Phase 3 study, sponsored by Denovo Biopharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 567
- Enrollment target
NCT01307800 is a Phase 3 study that was terminated before completion, run by Denovo Biopharma. The registered enrollment target is 567 participants.
The verdict
NCT01307800, a Phase 3 study, was terminated before completion, sponsored by Denovo Biopharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 567 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether at least 1 dose level of LY2140023 given to acutely ill patients with schizophrenia will demonstrate significantly greater efficacy as compared to placebo.
Interventions
- DRUG Placebo
- DRUG LY2140023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 567 participants |
| Start Date | 2011-03 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01307800
The ClinicalTrials.gov registry entry for NCT01307800 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 567 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Denovo Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01307800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01307800 about?
NCT01307800 is a clinical study titled "A Study of LY2140023 in Patients With Schizophrenia". The purpose of this study is to determine whether at least 1 dose level of LY2140023 given to acutely ill patients with schizophrenia will demonstrate significantly greater efficacy as compared to placebo.
What is the current status of trial NCT01307800?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 567 participants. The study started on 2011-03. Estimated completion is 2012-09.
What interventions are being tested in trial NCT01307800?
The interventions under investigation include: Placebo (DRUG), LY2140023 (DRUG).
Who is sponsoring clinical trial NCT01307800?
This trial is sponsored by Denovo Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.